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Abstract: Two novel squalene-derived triterpenes, spirodehydrovenustatriol (3) and  
14-keto-dehydrothyrsiferol (4) were isolated from the red alga Laurencia viridis, together 
with two new and unusual C17 terpenoids, adejen A (5) and B (6). These truncated 
structures possess structural similarities with other known squalene metabolites and their 
biogenetic origin has been proposed on the basis of an oxidative process of the squalene 
skeleton. All the structures were elucidated by extensive use of 2D NMR spectroscopic 
methods. 
Keywords: polyether; marine compound; triterpene; Laurencia viridis 
 
1. Introduction 
The Canary Current is characterised by an intense meso-scale structure in the transition zone 
between the cool and nutrient-rich water of the coastal upwelling regime and the warmer oligotrophic 
water of the open ocean. The Canary Islands, which straddle the transition, introduce a second source 
of variability by perturbing the general southwestward flow of both ocean current and trend winds. The 
combined effects of the flow disturbance and the eddying and meandering of the boundary between 
upwelled and oceanic waters produce a complex pattern of regional variability [1]. 
From this very brief description of the Canary’s coastal environment, it is easy to understand that 
finding a large variety of microecosystem with a rich marine biodiversity, is possible. Within these 
OPEN ACCESS
Mar. Drugs 2010, 8                          
 
 
1179
indigenous species, Laurencia viridis is a seasonal alga that grows on basaltic rocks in the lower 
intertidal zone during early spring when the costal temperature is about 18 °C, moderate wind forces 
and the resulting convection have a maximum penetration into the surface mixed layer [2]. From this 
alga, we have isolated a complex series of polyether secondary metabolites derived from squalene. These 
metabolites show a large diversity of ring sizes and functionalization [3–10]. Dehydrothyrsiferol (1) and 
dehydrovenustratriol (2) differentiated only by the configuration of carbons C-18 and C-19 are 
probably the best-known metabolites of these series (Figure 1). Furthermore, important pharmacologic 
properties as potent cytotoxic effects, protein phosphatase type 2A inhibition and integrin antagonist 
activity have been described for them [11–14].  
Figure 1. Representative polyether metabolites and new triterpene compounds isolated 
from Laurencia viridis. 
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3 Spirodehydrovenustatriol    4 14-keto-dehydrothyrsiferol 
In addition to previous work, we now report the isolation of four new compounds from this algae: 
spirodehydrovenustatriol (3) and 14-keto-dehydrothyrsiferol (4) belonging to the venustatriol and 
thyrsiferol series, respectively; in addition to two unusual the C17 terpenoids, adejen A (5) and B (6). 
These structures were fully established from their spectral data, and the relative stereochemistries and 
3D structures were proposed on the basis of ROESY, NOEDIFF analysis and conformational  
search studies. 
2. Results and Discussion 
Spirodehydrovenustatriol (3) was isolated as an amorphous white solid, [α]25D + 4.3 (c 0.61, CHCl3) 
and its molecular formula was established as C30H51O7Br by ESI-HRMS. The MS data were further 
supported by the analysis of the 13C-NMR chemical shifts of 3, where seven methyl, eleven methylene, 
and five methine groups, as well as six oxygenated and one olefinic quaternary carbons were  
identified (Table 1). 
Comparison of the NMR spectral data of compound 3 with those reported for dehydrovenustatriol (2) 
and derivatives isolated in our laboratory [5–10], showed some differences around the C-7→C-14 
fragment. On the other hand, fragments C-1→C-6 and C-15→C-24 turned out to be identical to those 
observed in dehydrovenustatriol (2) [9]. Analysis of the COSY spectrum allowed us to determine the 
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connectivity’s within the five 1H-1H spin systems present in this molecule, giving the partial structures 
shown in Figure 2. The proton assignments in the C-7→C-14 region may be conveniently started from 
H-7 (δH 3.65, d, J = 7.0 Hz), which was coupled with H2-8 (δH 1.78/1.87), and these sequentially to 
H2-9 (δH 1.59/1.88). Within the next spin system, H2-12 (δH 1.87/2.09) was coupled to H2-13  
(δH 1.78/2.07), and these in turn to H-14 (δH 3.98, dd, J = 5.0, 8.4 Hz). The HMBC correlations of the 
protons H2-9 and H3-27 (δH 1.11) with the quaternary carbon C-10 (δC 72.9) as well as those the 
protons H2-12, H2-13 and H3-27 with C-11 (δC 109.9), positioned the methyl group C-27 at the 
oxygen-bearing carbon C-10 and linked both partial structures through the ketal quaternary carbon  
C-11, indicating at the same time that both rings are linked by a spiroketal at this position. 
Figure 2. Structure of spirodehydrovenustatriol (3). 1H-1H spin systems are represented by 
coloured bold lines, while important HMBC correlations are represented by arrows. 
 
The relative configuration of the stereocentres C-3, C-6, C-7, C-10, C-18, C-19 and C-22 were 
established as identical to those found in venustatriol series on the basis of correlations observed in the 
ROESY experiment as well as through interpretation of NMR coupling constants data [5,9]. 
Furthermore, the relative configuration of the new spiroketal carbon was established as S* on the basis 
of the cross-correlation peak observed in the ROESY experiment between protons, H-14 and H3-27 
that can only be explained by the proposed orientation as is shown in Figure 3. 
Figure 3. Important ROESY correlations observed for B-C ring system in compound 3. 
    
The next compound, 14-keto-dehydrothyrsiferol (4), proved to have the same molecular formula as 3, 
(C30H51O7Br) on the basis of the result obtained from ESI-HRMS. Nevertheless, comparison of the 
13C-NMR spectral data between compounds 3 and 4 showed the absence of the characteristic 
spiroketal carbon C-11 (δC 109.9) as well as the existence of a new carbonyl signal at δC 202.3 
together with the absorption in the UV spectrum characteristic of an α,β-unsaturated ketone. These 
data, in concert with the interpretation of the 2D NMR spectra and comparison with the previously 
reported compounds [5–10], clearly indicated that the main differences between both compounds where 
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located at the C-7→C-14 fragment (Table 1). Thus, the connectivity’s observed in the COSY and 
HSQC experiments made it possible to assign these fragments as follows: the first spin system was 
started by the methine proton H-7 (δH 2.97, dd, J = 1.7, 11.0 Hz) coupled with both H2-8 (δH 1.38/1.76), 
which were in turn correlated to H2-9 (δH 1.48/1.82). The next spin system was formed by the methine 
proton H-11 (δH 3.03, dd, J = 1.2, 10.3 Hz) that connected with H2-12 (δH 1.51/2.01). These were 
further correlated to H2-13 (δH 2.71/2.87) (Figure 4). These substructures were joined together using 
the HMBC experiment whereby the protons H3-26 (δH 1.19) were correlated with carbons  
C-5 (δC 36.7), C-6 (δC 74.6) and C-7 (δC 86.1); the signal of H3-27 (δH 1.15) showed correlations with 
C-9 (δC 39.8), C-10 (δC 69.9) and C-11 (δC 83.7); and the typical carbonyl signal centred at δC 202.3 
(C-14) was correlated from the protons H2-13, H2-16 (δH 2.39/2.54) and H2-28 (δH 5.80/6.01). Finally, 
analysis of the ROESY experiment confirmed the relative stereochemistry of all chiral centres 
presented in the molecule as equivalent to those observed in the metabolites belonging to the 
thyrsiferol series. It has to be noted that this metabolite has a special interest from a biogenetic point of 
view, with regard to the next two compounds described in this paper. 
Table 1. NMR chemical shift data (CDCl3) for compounds 3 and 4. 
 Spirodehydrovenustatriol (3) 14-Keto-dehydrothyrsiferol (4) 
nº C  δ13C δ1H Mult J (Hz) δ13C δ1H Mult J (Hz) 
1 29.7 1.28 (3H) s  31.1 1.27 (3H) s  
2 74.9    75.0    
3 59.1 3.90 dd 4.0;12.1 58.8 3.88 dd 4.0;12.6 
4 29.3 2.12(α)/2.23(β)   28.2 2.10(α)/2.25(β)   
5 36.1 1.64 (2H)   36.7 1.55(α)/1.77(β)   
6 74.8    74.6    
7 88.1 3.65 d 7.0 86.1 2.97 dd 1.7;11.0 
8 27.6 1.78(β)/1.87(α)   23.5 1.38(β)/1.76(α)   
9 34.3 1.59(α)/1.88(β)   39.8 1.48(α)/1.82(β)   
10 72.9    69.9    
11 109.9    83.7 3.03 dd 1.2;10.3 
12 33.7 1.87/2.09   23.8 1.51/2.01   
13 26.6 1.78/2.07   34.6 2.71/2.87   
14 83.3 3.98 dd 5.0;8.4 202.3    
15 145.8    148.5    
16 30.9 2.32/2.57   28.2 2.39/2.54   
17 29.1 1.50/1.82   30.7 1.37/1.60   
18 75.2 3.82 dd 2.5;11.7 75.9 3.48 dd 1.5;10.5 
19 84.6    86.0    
20 35.0 1.61/2.01   31.5 1.56/2.09   
21 24.7 1.77 (2H)   26.6 1.83 (2H)   
22 86.7 3.76 dd 7.0;8.3 87.7 3.75 dd 6.1;10.0 
23 70.6    70.5    
24 25.4 1.11 (3H) s  23.9 1.12 (3H) s  
25 24.1 1.41 (3H) s  23.5 1.40 (3H) s  
26 21.1 1.20 (3H) s  20.3 1.19 (3H) s  
27 22.7 1.11 (3H) s  20.1 1.15 (3H) s  
28 107.0 4.77/4.91 bs/bs  124.5 5.80/6.01 bs/bs  
29 23.9 1.12 (3H) s  23.9 1.12 (3H) s  
30 28.2 1.20 (3H) s  27.7 1.21 (3H) s  
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Figure 4. Structure of 14-keto-dehydrothyrsiferol (4). 1H-1H spin systems are represented 
by coloured bold lines, while important HMBC correlations are represented by arrows. 
 
The molecular formulae of adejen A (5) and B (6), C17H27O3Br and C17H27O4Br, respectively, 
together with the fact that their 1H- and 13C-NMR spectra were reminiscent of the corresponding 
partial spectral signals of thyrsenol A led us to a quick identification of the structures of both 
compounds [7]. Both compounds share identical A-B ring moiety, whereas the only notable 
differences were fixed going towards the methine group at carbon C-11. In adejen A (5), the COSY 
spectrum revealed coupling between the methine proton H-11 (δH 3.35, dd, J = 5.8, 10.6 Hz) and the 
allylic methylene signals H2-12 at δH 1.88/2.04, which were in turn coupled to the olefinic proton H-13 
(δH 4.58, ddd, J = 2.0, 5.8 and 5.8 Hz) implicated in a Z olefin together with H-14 (δH 6.14, ddd,  
J = 1.4, 2.6 and 5.8 Hz) (Table 2). Furthermore, the characteristic chemical shifts of C-13 and C-14 at 
δC 98.1 and 141.7 respectively; in addition with the HMBC correlations for the bearing oxygen C-10 
(δC 74.3) with the olefinic proton H-14 indicated that this compound includes an enol-ether  
ring system. 
Figure 5. Structure proposed for C17 terpenoid compounds 5 (left) and 6 (right). 
   
A similar analysis for adejen B (6) revealed that H-11 centred at δH 3.43 (dd, J = 5.4, 12.1 Hz) was 
connected with protons H2-12 at δH 1.80/1.90 using the COSY experiment, that are also coupled with 
the methylene protons H2-13, δH 2.66/2.75. In addition, H2-13 showed correlations in the HMBC with 
a carbonyl signal at δC 170.2 (C-14), a clue that, in agreement to the strong band observed in the IR 
spectra at 1739 cm−1, established the existence of a lactone moiety. The proposed structures for 
compounds 5 and 6, including the same relative configuration found either in the thyrsiferol or 
venustatriol series, were consistent with the correlations observed in the ROESY experiment. 
From a biogenetic point of view, the discovery of the compounds described here support our 
previous proposal that the cyclization mechanism should be sequential as opposed to the classic 
hypothesis involving a concerted biogenetic mechanism. The discovery of a biogenetic intermediate 
such as 4 with a carbonyl group at C-11 should be considered the key to explain the formation of the 
compound such as thyrsenol A [6]. The compounds that possess an unusual truncated C17 carbon 
skeleton may be their biogenetical origin is 14-keto-dehydrothyrsiferol (4), that may arise from a 
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oxidative degradation followed by a cyclization process to become the corresponding enol-ether 5 or 
lactone ring 6, respectively.  
Table 2. NMR chemical shift data (CDCl3) for compounds 5 and 6. 
 Adejen A (5) Adejen B (6) 
nº C δ13C δ1H Mult J (Hz) δ13C δ1H Mult J (Hz) 
1 31.4 1.27 (3H) s  30.9 1.27 (3H) s  
2 75.4    75.1    
3 59.4 3.89 dd 4.1;12.3 58.5 3.88 dd 4.1;12.4 
4 28.8 2.11(α)/2.25(β)   28.1 2.11(α)/2.25(β)   
5 37.5 1.53(α)/1.83(β)   36.9 1.54(α)/1.81(β)   
6 74.6    74.1    
7 86.8 3.09 dd 2.5;11.4 86.7 3.15 dd 2.5;11.6 
8 23.3 1.51(β)/1.83(α)   22.4 1.47(β)/1.88(α)   
9 36.9 1.61(α)/1.89(β)   36.7 1.74(α)/1.99(β)   
10 74.3    78.7    
11 77.2 3.35 dd 5.8;10.6 76.5 3.43 dd 5.4;12.1 
12 24.5 1.88(β)/2.04(α)   21.6 1.80(β)/1.90(α)   
13 98.1 4.58 ddd 2.0;5.8;5.8 28.1 2.66/2.75   
14 141.7 6.14 ddd 1.4;2.6; 5.8 170.2    
15 24.1 1.41 (3H) s  23.6 1.41 (3H) s  
16 20.3 1.21 (3H) s  20.0 1.21 (3H) s  
17 15.9 1.14 (3H) s  19.3 1.36 (3H) s  
Once the planar structure and the relative stereochemistry of compounds 3 to 6 were determined, a 
conformational study was carried out in order to corroborate our previous hypothesis about the 
importance of the orientation of the C-15 to C-25 flexible moiety in the cytotoxic activity of these 
polyethers [11]. Thus, the crystal structure of 23-thyrsiferyl acetate was used as a template to build the 
structures by removal of the appropriate covalent bonds [15]. The chirality of the new stereocentres 
was then adapted according to the experimental data and the resulting structures were used as the 
starting point for the conformational searches (Figures 6–8).  
Figure 6. Conformational analysis results of 14-keto-dehydrothyrsiferol (4). The two low 
energy conformation of 14-keto-dehydrothyrsiferol in CDCl3 solution. Conformational 
Family: A (C: gray, O: red, Br: green); B (C: black, O: garnet, Br: green). 
  
Conformer 
Conformational 
Family 
Potential Energy 
(KJ/mol) 
Boltzman 
Distribution 
1 A 0.0 11.6 
2 A 0.67 8.8 
3 A 3.04 3.4 
4 A 3.22 3.2 
5 B 3.32 3.1 
6 B 3.38 3.0 
7 A 3.98 2.3 
8 A 4.16 2.2 
9 B 5.44 1.3 
10 A 5.48 1.3 
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Figure 7. Conformational analysis results of spirodehydrovenustatriol (3) in CDCl3 
solution. (C: gray; O: red; Br: green). 
  
Based on previous results obtained in our laboratory with this kind of molecules, two independent 
conformational searches for compounds 3 and 4 using the MMFF94s [16] force field as implemented 
in MacroModel 8.5 using the generalized Born/surface area (GBSA) solvent model for chloroform 
were undertaken [11,16]. Random searches of 10,000 MCMM steps were undertaken for each 
compound to ensure that the potential energy surface was explored using the TNCG algorithm. All 
local minima within 50 kJ of the global minimum were saved and subsequently re-minimized using the 
FMNR algorithm and an energy cutoff of 25 kJ to save the resulting molecules. On the other hand, for 
compounds 5 and 6, due to their conformational limitations, we used a systematic search around the 
only single bond connecting C-6 and C-7. 
With regard to 4, our conclusion after an analysis of the conformational search results was that this 
molecule is likely to exist in a fast conformational equilibrium between two different families of 
structures as shown in Figure 6. In fact, it can be calculated from the estimated populations by a 
Boltzmann distribution at 300 K that these conformational families constitute 53.7% (A) and 23.9% (B), 
of all structures within a 10 kJ/mol cut-off. On the other hand, the results obtained from the 
conformational search undertook for 3 showed a molecule with a less complicated conformational 
behavior. Even though 3 has a long acyclic moiety between C14 and C19, it seems that it clearly 
adopts a preferred “global folding” in solution, where only the C18-C19 bond appears to fluctuate. As 
a result the C19-C22 ring occupies two different positions. 
Finally, for adejen A (5) and B (6), the result of the systematic conformational search indicated that 
the global minimum corresponds to a value of ∼180° for the dihedral angle C-16–C-6–C-7–H-7 as 
showed in Figure 8. The obtained results are in full agreement with the ROESY derived data for both 
compounds, giving confidence in the theoretically obtained structures. 
Biological assays of the pure compounds 3, 5 and 6 were undertaken. Cytotoxic effects were 
evaluated with a couple of breast cancer cell lines (Hs578T and T47D) due to the well-known activity 
of this kind of compounds against them [5]. However, the result of these bioassays was that none of 
the studied compounds showed any activity below the 10 μg/mL concentration limit. 
 
Conformer Potential Energy (KJ/mol) 
Boltzman Distribution
(298 K) 
1 0.0 51.1 
2 3.47 12.7 
3 4.85 7.3 
4 6.08 4.5 
5 6.60 3.6 
6 7.3 2.7 
7 7.5 2.5 
8 8.5 1.7 
9 8.5 1.7 
10 8.8 1.5 
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Figure 8. Best energy structure found for C17 terpenoid, adejen B (6). Significant ROE 
correlations are shown in the Newman projection of the C-6–C-7 bond.  
  
3. Experimental Section  
3.1. General methods 
Optical rotations were determined on a Perkin-Elmer 241 polarimeter. IR spectra were measured on 
a Bruker IFS55 spectrometer. The NMR spectra were obtained with a Bruker 500 AMX, and Bruker 
400 and 300 Advance instruments. Chemical shifts are reported relative to TMS and coupling 
constants are given in Hz. HRMS were performed on a VG AutoSpec FISON spectrometer. HPLC was 
carried out with a LKB 2248 system equipped with a differential diffractometer detector. Silica gel CC 
and TLC were performed on Silica gel Merck 60 G. TLC plates were visualised by spraying with 
H2SO4/H2O/AcOH (1:4:20) and heating. 
3.2. Plant material 
The specimens of Laurencia viridis were collected in March 2008 in Callao Salvaje, Paraiso Floral, 
Adeje (Tenerife, Canary Island). A voucher specimen was deposited at the herbarium of the La Laguna 
University, Department of Vegetal Biology, Botany, Tenerife). 
3.3. Extraction and chromatographic separation 
The fresh alga was extracted with a 1:1 mixture of CHCl3-MeOH at room temperature. The extract 
was concentrated to yield a crude extract of 83.0 g. This material was chromatographed on a Sephadex 
LH-20 column using CHCl3-MeOH (1:1). Fractions that were similar in composition as shown by TLC 
were combined to give four fractions. The second fraction (53.4 g) was further separated by silica gel 
eluted with increasing concentrations of EtOAc in n-hexane followed by a medium pressure 
chromatography Lobar LiChroprep-RP18 with H2O-MeOH (9:1) as eluent. Final purification was 
carried out by HPLC employing μ-Porasil column and using n-hexane-EtOAc in different proportions 
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affording the pure new compounds spirodehydrovenustatriol (3, 6.1 mg), 14-ketodehydrothyrsiferol  
(4, 4 mg), 5 (3.0 mg) and 6 (2.6 mg). 
Spirodehydrovenustatriol (3): Amorphous white solid; [α]25D + 4.3 (c 0.61, CHCl3); IRνmax (CHCl3) 
2928, 2858, 1729, 1590, 1468, 1380 and 1038 cm−1; ESI-MS m/z 609, 607, 585, 545, 425, 413 and 
301; ESI-HRMS m/z 607.2618 (Calcd. for C30H49O679BrNa, 607.2610, [M–H2O+Na]+); 1H-NMR  
(400 MHz, CDCl3) see Table 1. 
14-keto-dehydrothyrsiferol (4): Amorphous white solid; [α]25D + 3.9 (c 0.18, CHCl3); UV λmax 
(CHCl3) 239.8 (ε 1630) (log ε = 3.2); IRνmax (CHCl3) 3438, 2973, 2865, 1587, 1443, 1379 and  
1094 cm−1; EI-MS m/z 627, 625, 609, 607, 413, 301 and 172; ESI-HRMS m/z 625.2708 (Calcd. for 
C30H51O779BrNa, 625.2716, [M + Na]+); 1H-NMR (400 and 500 MHz, CDCl3) see Table 1. 
Adejen A (5): Amorphous white solid; [α]25D + 1.9 (c 0.30, CHCl3); IRνmax (CHCl3) 2928, 2858, 1728, 
1590, 1450 and 1383 cm−1; ESI-HRMS m/z 381.1035 (Calcd. for C17H27O379BrNa, 381.1041,  
[M + Na]+); 1H-NMR (400 and 500 MHz, CDCl3) see Table 2. 
Adejen B (6): Amorphous white solid; [α]25D + 8.6 (c 0.26, CHCl3); IRνmax (CHCl3) 3570, 2951, 2349, 
1739, 1584 and 1468 cm−1; ESI-HRMS m/z 397.0982 (Calcd. for C17H27O479BrNa, 397.0990,  
[M + Na]+); 1H-NMR (400 and 500 MHz, CDCl3) see Table 2. 
3.4. Biological activity 
Breast cancer cell lines Hs578T and T47D were cultured in Dulbecco’s Minimum Essential 
Medium (DMEN) supplement with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 100 U/mL 
penicillin and streptomycin using standard protocol and seeded in 200 μL wells. After preincubation 
(37 °C, 5% CO2 for 24 h), cells were exposed to graded concentrations of compounds in triplicate  
(37 °C, 5% CO2 for 48 h). For quantitative estimation of cytotoxicity, the colorimetric XTT method 
was used. Thus, the cells were treated with 50 μL of XTT solution (1 mg/mL in PBS) after removal of 
the medium and incubated for 3 h. Residual formazan was then separated from the aqueous solution 
with DMSO (100 μL) and the absorbance was measured using a Bio-Rad at 490 nm. IC50 values were 
estimated by plotting absorbance values against concentrations. Adriamycin and DMSO were used as 
the positive and negative control in this bioassay [18]. 
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